# Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

> **NCT06419946** · PHASE3 · RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 200 (estimated)

## Conditions studied

- Glioblastoma, IDH-wildtype
- MGMT-Methylated Glioblastoma

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT06419946
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2031-12-15
- **Final completion:** 2033-12-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06419946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06419946, "Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06419946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*